Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Atif Zaheer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4824-6654; OpenAlex author ID A5072874954. Sources: ClinicalTrials.gov.

Their work

Papers
21 (first author 3, last author 6)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
99
Papers, trials and grants by year

2013: 1 trial · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 4 papers · 2019: none · 2020: 3 papers · 2021: 1 paper · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 21

  1. Prevalence and Imaging Characteristics of Chronic Calcific Pancreatitis in Patients With Newly Diagnosed Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/rct.0000000000001916↗
  2. Artificial Intelligence Outperforms Radiologists in Pancreatic Cancer Detection. Co-author DOI 10.2214/ajr.26.34569↗
  3. ACR Appropriateness Criteria® Screening, Locoregional Assessment, and Surveillance of Pancreatic Ductal Adenocarcinoma: 2025 Update. First author DOI 10.1016/j.jacr.2025.08.037↗
  4. Factors Associated With Aborted Whipple Procedures for Periampullary Carcinoma: A Multicenter Case-Control Study by the SAR Pancreatic Ductal Adenocarcinoma Di… Co-author DOI 10.2214/ajr.24.32160↗
  5. Imaging Surveillance of High Risk-Patients for Early Detection of Pancreatic Cancer Last author DOI 10.1053/j.ro.2024.11.004↗
  6. Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of ab… Last author DOI 10.1007/s00261-022-03693-0↗
  7. Structured CT reporting of pancreatic ductal adenocarcinoma: impact on completeness of information and interdisciplinary communication for surgical planning. Last author DOI 10.1007/s00261-021-03353-9↗
  8. Location, Location, Location: What Should be Targeted Beyond Gross Disease for Localized Pancreatic Ductal Adenocarcinoma? Proposal of a Standardized Clinical … Co-author DOI 10.1016/j.prro.2022.01.005↗
  9. The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience. Co-author DOI 10.1067/j.cpradiol.2022.05.001↗
  10. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  11. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  12. Pitfalls in the MDCT of pancreatic cancer: strategies for minimizing errors. Co-author DOI 10.1007/s00261-019-02390-9↗
  13. Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional im… Co-author DOI 10.1007/s00261-020-02723-z↗
  14. Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04230-z↗
  15. Imaging of post-operative pancreas and complications after pancreatic adenocarcinoma resection. Last author DOI 10.1007/s00261-017-1378-y↗
  16. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease. First author DOI 10.1007/s00261-017-1410-2↗
  17. Multi-institutional survey on imaging practice patterns in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00261-017-1433-8↗
  18. Metastatic Pancreatic Adenocarcinoma in a Patient With Chronic Calcific Pancreatitis and a Heterozygous SPINK1 c.194+2T>C Mutation. Co-author DOI 10.1097/mpa.0000000000001015↗
  19. Tumor-Vessel Relationships in Pancreatic Ductal Adenocarcinoma at Multidetector CT: Different Classification Systems and Their Influence on Treatment Planning. Last author DOI 10.1148/rg.2017160054↗
  20. Pearls and pitfalls of imaging metastatic disease from pancreatic adenocarcinoma: a systematic review. Co-author DOI 10.1016/j.clinimag.2015.04.017↗
  21. Differentiating autoimmune pancreatitis from pancreatic adenocarcinoma using dual-phase computed tomography. Co-author DOI 10.1097/rct.0b013e3182a9a431↗

Trials 1

  1. Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis Principal investigator NCT01845467↗

Closest collaborators

The 25 strongest of 99 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elliot K. Fishman · 11 shared papers, 2014–2023 · strength 1.15
  2. Jin Peng He · 8 shared papers, 2020–2025 · strength 0.99
  3. Amol Kumar Narang · 6 shared papers, 2021–2023 · strength 0.74
  4. Erik V. Soloff · 5 shared papers, 2018–2025 · strength 0.57
  5. Vikesh K. Singh · 5 shared papers, 2014–2026 · strength 0.56
  6. Satomi Kawamoto · 4 shared papers, 2014–2026 · strength 0.54
  7. Linda Chi Hang Chu · 4 shared papers, 2020–2025 · strength 0.54
  8. Marc Zins · 4 shared papers, 2018–2025 · strength 0.50
  9. Avinash R. Kambadakone · 4 shared papers, 2018–2025 · strength 0.47
  10. Ammar A. Javed · 5 shared papers, 2017–2022 · strength 0.46
  11. Rubab F. Malik · 2 shared papers, 2022–2026 · strength 0.42
  12. Daniel A. Laheru · 4 shared papers, 2021–2023 · strength 0.42
  13. Ralph H. Hruban MD · 4 shared papers, 2020–2022 · strength 0.41
  14. Eric Peter Tamm · 4 shared papers, 2018–2023 · strength 0.40
  15. Zhen J. Wang · 3 shared papers, 2020–2025 · strength 0.39
  16. Richard Kinh Gian Do · 3 shared papers, 2020–2025 · strength 0.39
  17. Christopher Lee Wolfgang · 4 shared papers, 2017–2022 · strength 0.38
  18. Eun Ji Shin · 4 shared papers, 2020–2022 · strength 0.38
  19. Richard Andrew Burkhart · 4 shared papers, 2020–2022 · strength 0.38
  20. Mostafa Alnoury · 1 shared paper, 2024 · strength 0.36
  21. Anne Marie Lennon · 4 shared papers, 2018–2022 · strength 0.35
  22. Priya Bhosale · 3 shared papers, 2018–2023 · strength 0.30
  23. Samuel Joseph Galgano · 2 shared papers, 2023–2025 · strength 0.29
  24. Lyndon Luk · 2 shared papers, 2023–2025 · strength 0.29
  25. Candice W. Bolan · 2 shared papers, 2023–2025 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.